The new center is seen as a worldwide bridge among scientists, researchers and physicians in their pursuit of new diagnostics and therapeutics to benefit patientsContinue reading→

Funding expands manufacturing readiness for Valley fever vaccine.  This follows Anivive’s $33MM NIAID contract for fungal vaccines
In total, Anivive has secured over $80MM in contracts and preordersContinue reading→

Report shows ASU is a major economic engine driving the state through investments, spinoffs, research, taxes paid by alumni and more.Continue reading→

Focuses genomic and proteomic lenses on three canine cancers
Continue reading→

New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-PathContinue reading→

Experimental, three-drug chemotherapy regimen didn’t improve survival rates for patients, but treatment might still prove helpful for a small subset of patients.Continue reading→

Financing Led by Evidity Health Capital Continue reading→

XLR8 PBC is an 8-day intensive program for scale-ready (series A/B) companies seeking the capital, experience, and industry validation to move to the next level. The program emphasizes finding the right capital at the right time, growth-stage executive matchmaking, and corporate partnerships to validate market fit. With resources like access to innovative collision spaces, student analysts, and a robust ecosystem, XLR8 is dedicated to enhancing the growth potential of scale-ups.Continue reading→

The National Institutes of Health (NIH) has recognized the Syn-One Test as one of its “Top Promising Medical Findings for 2024”. The skin-biopsy test is the first commercially available test of its kind that can detect phosphorylated alpha-synuclein (P-SYN), a protein indicative of Parkinson’s disease (PD) and related synucleinopathies, including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF).Continue reading→